Japan-based Takeda Pharmaceutical has acquired a 215,000-square-foot biotech plant in Brooklyn Park, Minnesota, with the intention of manufacturing its recently-approved digestive-tract drug, Entyvio.
Last September, Baxalta announced it was selling the Minnesota facility, acquired from Genmab in 2013, as part of its new outsourcing strategy for biosimilars.
This will be Takeda’s first manufacturing plant in the United States. Besides its main purpose of manufacturing the injectable biologic, Entyvio, the new plant gives it the capability to manufacture other commercial and investigational drugs still under development.
Read the Star Tribune article